Search research articles
Contact Us
Filters
Showing results (71-80 of 104) with videos related to
Page
of 11
Sort By:
Journal of Cancer Research and Clinical Oncology
|
January 12, 2021
Prognostic impact of rapid reduction of involved free light chains in multiple myeloma patients under first-line treatment with Bendamustine, Prednisone, and Bortezomib (BPV)
Tanja Holzhey, Wolfram Pönisch, Song-Yau Wang, et al.
Blood
|
February 13, 2009
MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1
Ramiro Garzon, Shujun Liu, Muller Fabbri, et al.
Transfusion
|
October 18, 2023
Steady-state versus chemotherapy-based hematopoietic cell mobilization after anti-CD38-based induction therapy in newly diagnosed multiple myeloma
Raphael Teipel, Susanne Rieprecht, Karolin Trautmann-Grill, et al.
Journal of Cancer Research and Clinical Oncology
|
August 20, 2022
Impact of the changing landscape of induction therapy prior to autologous stem cell transplantation in 540 newly diagnosed myeloma patients: a retrospective real-world study
Song-Yau Wang, Tanja Holzhey, Simone Heyn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 8, 2013
Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients
Guido Marcucci, Kati S Maharry, Klaus H Metzeler, et al.
Journal of Cancer Research and Clinical Oncology
|
May 16, 2015
Stem cell mobilization and autologous stem cell transplantation after pretreatment with bendamustine, prednisone and bortezomib (BPV) in newly diagnosed multiple myeloma
Wolfram Poenisch, Madlen Plötze, Bruno Holzvogt, et al.
Haematologica
|
June 11, 2011
Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study
Heiko Becker, Kati Maharry, Michael D Radmacher, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
April 7, 2010
Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine
William Blum, Ramiro Garzon, Rebecca B Klisovic, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 7, 2010
IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study
Guido Marcucci, Kati Maharry, Yue-Zhong Wu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 17, 2010
Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study
Sebastian Schwind, Kati Maharry, Michael D Radmacher, et al.
Page
of 11
Search research articles
Search
Showing results (71-80 of 104) with videos related to
Sort By:
Page
of 11
Journal of Cancer Research and Clinical Oncology
|
January 12, 2021
Prognostic impact of rapid reduction of involved free light chains in multiple myeloma patients under first-line treatment with Bendamustine, Prednisone, and Bortezomib (BPV)
Tanja Holzhey, Wolfram Pönisch, Song-Yau Wang, et al.
Blood
|
February 13, 2009
MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1
Ramiro Garzon, Shujun Liu, Muller Fabbri, et al.
Transfusion
|
October 18, 2023
Steady-state versus chemotherapy-based hematopoietic cell mobilization after anti-CD38-based induction therapy in newly diagnosed multiple myeloma
Raphael Teipel, Susanne Rieprecht, Karolin Trautmann-Grill, et al.
Journal of Cancer Research and Clinical Oncology
|
August 20, 2022
Impact of the changing landscape of induction therapy prior to autologous stem cell transplantation in 540 newly diagnosed myeloma patients: a retrospective real-world study
Song-Yau Wang, Tanja Holzhey, Simone Heyn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 8, 2013
Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients
Guido Marcucci, Kati S Maharry, Klaus H Metzeler, et al.
Journal of Cancer Research and Clinical Oncology
|
May 16, 2015
Stem cell mobilization and autologous stem cell transplantation after pretreatment with bendamustine, prednisone and bortezomib (BPV) in newly diagnosed multiple myeloma
Wolfram Poenisch, Madlen Plötze, Bruno Holzvogt, et al.
Haematologica
|
June 11, 2011
Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study
Heiko Becker, Kati Maharry, Michael D Radmacher, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
April 7, 2010
Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine
William Blum, Ramiro Garzon, Rebecca B Klisovic, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 7, 2010
IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study
Guido Marcucci, Kati Maharry, Yue-Zhong Wu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 17, 2010
Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study
Sebastian Schwind, Kati Maharry, Michael D Radmacher, et al.
Page
of 11